Page 36 - பாஷ் ஆரோக்கியம் நிறுவனங்கள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

in Taiwan May 4, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has launched VYZULTA ® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. VYZULTA has also recently received approval in Qatar. In addition to Taiwan, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020) and Hong Kong (2020), and is now approved in 5 other territories (Brazil, Colombia, Qatar, South Korea, and Ukraine). VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Bausch + Lomb will continue seeking approvals in t

New yorkUnited statesProvence alpes côd azurHong kongFrance generalUnited kingdomCity ofSouth koreaVictor floc hGavin spencerYi chenDamien choplainPharma bioMary ann changPooya hemamiSophia antipolis